01 / DUAL ACTIVE ASSAY
Standard Antidepressant + Anxiolytic Ratio
Each tablet contains Escitalopram 10 mg and Clonazepam 0.25 mg with strict active assay uniformity and rapid dissolution complying with Indian Pharmacopoeia standards.
Blessme · Antidepressants & Anxiolytics
Escitalopram + Clonazepam Tablets - ESICARE-LS
ESICARE-LS is an established fixed-dose combination oral tablet uniting Escitalopram Oxalate IP equivalent to Escitalopram 10 mg with Clonazepam IP 0.25 mg by Blessme, Dellwich Lifescience LLP. Specifically formulated for the maintenance treatment of comorbid depression and generalized anxiety disorder, it combines full-strength serotonergic mood elevation with low-dose GABAergic calming to maintain daytime functional productivity.
Standard Maintenance Therapy
Narcotic / Schedule H
Pan-India Supply
Product SpecificationsAbout Escitalopram + Clonazepam
About Escitalopram + Clonazepam
(ESICARE-LS)
Detailed pharmaceutical specifications, active API monograph compliance, low-sedation maintenance synergy, and 4x5x10 blister packaging details for ESICARE-LS.
Blessme · Antidepressant & Anxiolytic
Escitalopram + Clonazepam - ESICARE-LS
ESICARE-LS combines full-dose 10 mg Escitalopram with 0.25 mg Clonazepam. Formulated as a definitive maintenance therapy, it ensures continuous antidepressant efficacy while keeping panic surges and anxiety tension strictly under control.
10 mg Escitalopram Delivers Gold-Standard SSRI Efficacy 0.25 mg Clonazepam Calms Anxiety Without Day-Time Fatigue Preferred Choice for Working Professionals with Anxiety 4x5x10 Blister Strip Format for Tropical Protection Strict Indian Pharmacopoeia Quality Standards
- Product Brand Name
- ESICARE-LS
- Active Pharmaceutical Ingredients
- Escitalopram Oxalate IP eq. to Escitalopram 10 mg + Clonazepam IP 0.25 mgVerified IP
- Therapeutic Class
- Neuropsychiatric Antidepressant (SSRI) & Anxiolytic (Benzodiazepine)
- Dosage Form
- Oral Solid Compressed Tablet
- Strength Formulation
- 10 mg Escitalopram + 0.25 mg Clonazepam (Low Sedation Maintenance)
- Packaging Standard
- 4x5x10 Blister Strips (200 Tablets per Box)
- Regulatory Category
- Narcotic Drug
- Marketing Division
- Blessme · Neuro & Psychiatric Products
- Manufacturing Standard
- WHO-GMP & ISO 9001:2015 Certified Clean-Room Compression
- Storage Condition
- Store below 25°C in a dry place. Protect from light and moisture.
- Country of Origin
- India
Clinical & Commercial MonographEscitalopram + Clonazepam Tablet & ESICARE-LS
Escitalopram + Clonazepam Tablet & ESICARE-LS
Complete Medical & Supply Guide
In-depth pharmacological evaluation of Escitalopram 10 mg + Clonazepam 0.25 mg tablets, marketed as ESICARE-LS by Blessme (Dellwich Lifescience LLP). Covers maintenance therapy in comorbid mood and anxiety disorders, receptor mechanics, and pharmaceutical supply across India.
What is ESICARE-LS (Escitalopram 10 mg + Clonazepam 0.25 mg)?
ESICARE-LS is a fixed-dose oral neuropsychiatric tablet engineered for the long-term therapeutic management of mixed anxiety and depressive disorders. While Escitalopram 10 mg provides complete therapeutic reuptake inhibition to restore mood, Clonazepam 0.25 mg provides stable anxiolytic coverage.
When doctors and hospitals search for Escitalopram Clonazepam 10mg tablet or low-sedation SSRI anxiolytic combination, they look for reliable blend uniformity and clean clinical outcomes. ESICARE-LS delivers these qualities through automated clean-room manufacturing under WHO-GMP compliance.
Clinical Uses & Evidence-Based Indications
Approved neurological and psychiatric indications for ESICARE-LS include:
- Major Depressive Disorder (MDD) with Comorbid Anxiety: Gold-standard mood elevation with relief of psychic distress.
- Generalized Anxiety Disorder (GAD): Long-term reduction of chronic apprehension and somatic muscle tension.
- Panic Disorder with Agoraphobia: Prevents recurring panic attacks and reduces avoidance behaviors.
- Social Phobia / Social Anxiety Disorder: Sustained improvement in social confidence and reduced anticipatory fear.
- Obsessive-Compulsive Spectrum Symptoms: Adjunctive relief of intense intrusive anxiety.
Neurochemical Mechanism of Action: Dual Serotonergic & GABAergic Synergy
Escitalopram 10 mg is a highly selective serotonin reuptake inhibitor (SSRI) that binds to the primary site on the serotonin transporter protein (SERT) as well as an allosteric modulatory site. This dual binding stabilizes SERT inhibition, leading to sustained increases in extracellular 5-HT concentrations in the dorsal raphe projections to the frontal cortex.
Simultaneously, Clonazepam 0.25 mg acts as a positive allosteric modulator on the GABAA receptor-chloride ion channel complex. By increasing chloride influx, it hyperpolarizes limbic neurons, immediately terminating breakthrough anxiety and maintaining mental calmness throughout the day.
Formulation Comparison: ESICARE-LS vs. ESICARE-PLUS vs. ESICARE-PLUS-H
Clinical criteria for selecting between the formulations:
- ESICARE-LS (10 mg + 0.25 mg): Standard therapeutic antidepressant dose (10 mg) with micro-dose anxiolytic cover (0.25 mg) for long-term maintenance.
- ESICARE-PLUS (10 mg + 0.5 mg): Full-strength antidepressant with higher-potency anxiolytic (0.5 mg) for severe panic crises and severe agitation.
- ESICARE-PLUS-H (5 mg + 0.25 mg): Starting titration dose for sensitive patients, geriatric individuals, or mild anxiety-depression overlap.
Dosage Guidelines & Administration Method
ESICARE-LS must be taken strictly in accordance with medical advice:
- Standard Maintenance Dose: 1 tablet once daily, preferably in the morning or at night with water.
- Consistency: Take at the same time each day to ensure constant plasma drug concentrations.
- With or Without Food: Can be administered with meals to minimize potential initial mild nausea.
- Tapering Protocol: Do not discontinue abruptly; gradual tapering prevents discontinuation phenomena.
Critical Safety Warning - Schedule H / Narcotic Controlled Substance
ESICARE-LS contains Clonazepam, which carries potential for dependence and habit formation with prolonged therapy. Do not consume alcohol during therapy. Contraindicated with monoamine oxidase inhibitors (MAOIs). Dispensed strictly against a valid medical prescription.
Quality & Production
Pharmaceutical Quality Assurance & Compliance
ESICARE-LS is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity and maximum packaging stability.
02 / PROTECTIVE PACKAGING
High-Barrier Blister Foil
Tamper-evident, tropicalized 4x5x10 blister strips prevent moisture ingress and light-induced degradation, ensuring active ingredient stability across diverse Indian climates.
03 / PHARMACOPOEIA DOSSIERS
COA & Batch Testing Records
Every batch is backed by authenticated Certificates of Analysis (COA), disintegration profiles, assay validation data, and Material Safety Data Sheets for hospital audits.
04 / WHO-GMP COMPLIANCE
Schedule M Manufacturing
Produced in state-of-the-art accredited manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Clinical Profile & Precautions
Approved Indications & Regulatory Guidelines
Prescribing guidance, contraindications, and drug interactions for Escitalopram 10 mg + Clonazepam 0.25 mg tablets.
Prescription-Only Schedule H / Narcotic Medication Notice
ESICARE-LS is a Schedule H prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Clinical Indications Profile
Approved neurological and psychiatric indications for ESICARE-LS:
- Major Depressive Disorder: Rebalances core serotonergic neurotransmission.
- Generalized Anxiety Disorder: Provides daytime tranquilization without heaviness.
- Panic Disorder: Suppresses panic attacks and anticipatory fear.
- Social Anxiety: Normalizes affective responses in social settings.
Contraindications & Precautions
Key contraindications and monitoring requirements:
- MAOI Interaction: Never use concurrently with MAOIs; observe a 14-day washout period.
- QTc Interval Caution: Avoid concurrent use with medications prolonging the QT interval.
- Alcohol Prohibition: Dangerous synergism leading to severe hypotension and CNS depression.
- Gradual Discontinuation: Taper slowly under physician direction.
Manufacturing & Marketing
Dellwich Lifescience LLPBlessme · Neuro & Psychiatric Division
About Dellwich Lifescience
Trusted Neuro & Psychiatric Pharmaceutical Manufacturer in Ahmedabad, Gujarat
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including ESICARE-LS (Escitalopram 10 mg + Clonazepam 0.25 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Commercial PartnershipsESICARE-LS Supply &
ESICARE-LS Supply &
Pharmaceutical Distribution
Whether you are seeking ESICARE-LS for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Exclusive Monopoly PCD Franchise
Secure district-level monopoly marketing rights for ESICARE-LS and the Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Third-Party Contract Manufacturing
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Hospital & Institutional Procurement
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
Blessme · ESICARE-LS
Why Choose ESICARE-LS Tablets?
When sourcing Escitalopram Clonazepam tablets in India, ESICARE-LS by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
WHO-GMP Certified Purity
Manufactured in accredited facilities using IP grade APIs, ensuring exact active content uniformity and fast disintegration.
High-Barrier Blister Packaging
Tamper-evident, moisture-resistant blister strips protect tablets from ambient humidity and transport friction.
Pan-India Dispatch from Ahmedabad
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Monopoly PCD Franchise Rights
Exclusive district-level franchise rights for ESICARE-LS and the Blessme portfolio with promotional visual aids.
Comprehensive Regulatory Dossiers
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct Manufacturer Support
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Common Questions
Frequently Asked Questions about ESICARE-LS
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Escitalopram + Clonazepam tablets.
What is ESICARE-LS and what does it contain?
ESICARE-LS is a fixed-dose combination oral tablet from the Blessme division of Dellwich Lifescience. It contains Escitalopram Oxalate IP equivalent to Escitalopram 10 mg and Clonazepam IP 0.25 mg. The 'LS' signifies Low Strength Clonazepam, designed to provide steady antidepressant maintenance with gentle anxiolytic support.
Why is ESICARE-LS widely prescribed for depression with anxiety?
Depression and anxiety frequently coexist. Escitalopram 10 mg delivers proven, gold-standard SSRI antidepressant efficacy, while 0.25 mg Clonazepam dampens somatic restlessness, anticipatory worry, and sleep disturbances without heavy daytime grogginess.
How does ESICARE-LS differ from ESICARE-PLUS-H?
ESICARE-PLUS-H contains Escitalopram 5 mg + Clonazepam 0.25 mg (half-strength, for initial titration). ESICARE-LS contains full 10 mg Escitalopram + 0.25 mg Clonazepam (the definitive therapeutic maintenance dose).
How does ESICARE-LS differ from ESICARE-PLUS?
ESICARE-PLUS contains 0.5 mg of Clonazepam alongside 10 mg Escitalopram, providing stronger sedation and panic control for severe acute crises. ESICARE-LS provides 0.25 mg Clonazepam, preferred when daytime alertness and working functionality are priorities.
When should ESICARE-LS be taken?
ESICARE-LS is typically taken once daily, in the morning or at night, as recommended by the treating psychiatrist. Taking it consistently at the same time each day maintains steady therapeutic blood levels.
Will ESICARE-LS cause severe daytime sedation?
Because the Clonazepam strength is maintained at 0.25 mg, daytime sedation is significantly reduced compared to standard 0.5 mg formulations. Most working individuals tolerate ESICARE-LS with excellent mental clarity.
Can ESICARE-LS be stopped abruptly?
No. Abrupt stoppage can lead to SSRI discontinuation syndrome (flu-like symptoms, insomnia, irritability) and benzodiazepine rebound anxiety. Tapering must always be supervised by a medical professional.
Can I drink alcohol while taking ESICARE-LS?
Alcohol must be avoided. Combining alcohol with Escitalopram and Clonazepam can cause profound central nervous system depression, impaired judgment, memory blackouts, and heightened hypotension.
Is ESICARE-LS habit-forming?
Escitalopram has no dependence potential. However, Clonazepam carries mild dependence risk with prolonged continuous therapy. Doctors periodically assess the need for ongoing benzodiazepine co-administration.
What are common side effects of ESICARE-LS?
Common side effects include mild nausea, dry mouth, slight dizziness, changes in appetite, and mild drowsiness. These symptoms are usually temporary and diminish after the first 1 to 2 weeks of therapy.
Can patients with cardiac issues take ESICARE-LS?
Patients with pre-existing long QT syndrome or severe arrhythmias require clinical evaluation, as Escitalopram can have a modest dose-dependent effect on the QT interval.
How is ESICARE-LS packaged?
ESICARE-LS is packaged in 4x5x10 blister strips (200 tablets per box) manufactured with moisture-barrier foil to guarantee extended shelf life across all Indian climate conditions.
How can distributors apply for PCD franchise monopoly for ESICARE-LS?
Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.
Where does Dellwich Lifescience manufacture ESICARE-LS?
Manufactured in WHO-GMP certified facilities located in Gujarat, adhering to strict Indian Pharmacopoeia standards and automated validation procedures.
Direct Pharmaceutical Enquiry
Need Verified Information or Bulk Supply of ESICARE-LS?
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Direct Manufacturer Pricing & Transparent MOQ
Exclusive PCD Monopoly Rights for Designated Districts
Fast Dispatch from Ahmedabad with GST Invoicing
Comprehensive Marketing, Visual Aids & Promotional Inputs
Quick Assistance & Orders
Enquire About ESICARE-LS
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Escitalopram 10 mg + Clonazepam 0.25 mg Tablets.